Ellevest Inc’s Verrica Pharmaceuticals VRCA Stock Holding History

Ellevest Inc’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1708
2022 Q1	$0	Buy	+1	New	+$82	﹤0.01%	1645

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Ellevest Inc's VRCA Position: Q2 2022 in Review

Ellevest Inc sold out of Verrica Pharmaceuticals (VRCA) in Q2 2022, closing a stake of 1 share.

Ellevest Inc first reported a position in VRCA in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 57 funds tracked by Wall St. Rank hold VRCA as of Q2 2022.

Ellevest Inc reported no remaining Verrica Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ellevest Inc sold 1 Verrica Pharmaceuticals share in Q2 2022.
Ellevest Inc first reported a position in Verrica Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Ellevest Inc's Verrica Pharmaceuticals position peaked at $0 in Q1 2022.
57 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2022.

Based on Ellevest Inc's 13F filing for Q2 2022, filed 18 Jul 2022.